Exelixis Targeted As Activist Farallon Capital Partners Reveals 7.2% Holding

Exelixis

In the wake of a new EXEL stock buyback, the cancer therapies maker is in the sights of investors looking to make board changes It has been an eventful start to the week for investors of genomics-based drug discovery outfit Exelixis (NASDAQ:EXEL), after the company announced a share buyback worth $550 million pre-market and received […]